Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pegylated TOP1 inhibitor PEEL-224

A pegylated camptothecin derivative, with potential antineoplastic activity. Upon administration of pegylated TOP1 inhibitor PEEL-224, camptothecin reaches the tumor cells and selectively stabilizes covalent topoisomerase I-DNA complexes, which results in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. Pegylation allows for increases in half-life and the exposure time for tumor cells, while decreasing both blood plasma concentrations and exposure to off-target organs. This may increase efficacy and reduce systemic toxicities.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:topoisomerase-I inhibitor PEEL-224
Code name:PEEL 224
PEEL-224
PEEL224
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search